Research location
Warrenville
Illinois, United States
Advertisement
Research activity in Warrenville
Illinois, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 131 trials and 133 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Warrenville
131 linked trials · page 2 of 3Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerNCT05364645 · 2022-07-25 · 1 site observation
WITHDRAWN
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 2 site observations
ACTIVE_NOT_RECRUITING
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).NCT05227209 · 2022-03-17 · 1 site observation
TERMINATED
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.NCT05169710 · 2021-12-21 · 1 site observation
TERMINATED
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyNCT04455750 · 2021-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246 · 2021-08-05 · 1 site observation
TERMINATED
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking AbilityNCT04804644 · 2021-06-08 · 1 site observation
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE StudyNCT04316117 · 2020-09-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion StudyNCT04361240 · 2020-08-01 · 1 site observation
COMPLETED
A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsNCT04478279 · 2020-07-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialNCT04134260 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNCT03488693 · 2018-10-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate CancerNCT03561220 · 2018-07-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209 · 2018-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelNCT03419234 · 2018-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 1 site observation
COMPLETED
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)NCT02595944 · 2016-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).NCT02831959 · 2016-07-01 · 1 site observation
COMPLETED
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)NCT02709655 · 2016-05-18 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung CancerNCT02635009 · 2015-12-22 · 1 site observation
COMPLETED
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective RegistryNCT02670577 · 2015-11-01 · 1 site observation
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNCT02488967 · 2015-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves SurvivalNCT02364557 · 2014-12-24 · 1 site observation
COMPLETED
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01 · 1 site observation
COMPLETED
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · 2014-10-01 · 1 site observation
COMPLETED
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · 2014-09-01 · 1 site observation
COMPLETED
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate CancerNCT02141438 · 2014-08-20 · 1 site observation
COMPLETED
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · 2014-07-31 · 1 site observation
COMPLETED
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08 · 1 site observation
COMPLETED
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · 2014-06-16 · 1 site observation
TERMINATED
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticNCT02115282 · 2014-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryNCT01953588 · 2014-02-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.